NCT02504372 · OUTCOME

Lung Cancer Specific Survival (LCSS)

Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) · Source last updated 2026-03-17

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to approximately 132 months

What was measured

LCSS was defined as the time from randomization to the date of death (due to lung cancer specifically).

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2028-02
denom Units Selected: Participants
description: LCSS was defined as the time from randomization to the date of death (due to lung cancer specifically).
reporting Status: NOT_POSTED
time Frame: Up to approximately 132 months
title: Lung Cancer Specific Survival (LCSS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice